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Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder
affecting upper and lower motor neurons (MNs), resulting in paralysis and preco-
cious death from respiratory failure. Although the causes of ALS are incompletely
understood, the role of alterations in RNA metabolism seems central. MicroRNAs
(miRNAs) are noncoding RNAs implicated in the regulation of gene expression of
many relevant physiological processes, including cell death. The recent model of
programmed cell death (PCD) encompasses different mechanisms, from apoptosis to
regulated necrosis (RN), in particular necroptosis. Both apoptosis and necroptosis
play a significant role in the progressive death of MNs in ALS. In this review, we
present key research related to miRNAs that modulate apoptosis and RN pathways
in ALS. We also discuss whether these miRNAs represent potential targets for ther-
apeutic development in patients.
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1 | INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease
characterized by the progressive degeneration of both upper and
lower motor neurons (MNs), which results in muscle paralysis and
ultimately death from respiratory failure within a median of 3 years.1
At present, no effective therapy is available for ALS. Riluzole and
Edaravone are the sole two drugs approved for ALS but only mod-
estly slow disease progression.1,2
Patients affected by idiopathic ALS and without a family history
are classified as sporadic (sALS). A fraction of cases (approximately
10%) are familial (fALS), because of mutations in genes involved in a
wide range of cellular functions, encompassing roles in motor neu-
ronal and non‐neuronal cells.3,4
Since the first identification, in 1993, of superoxide dismutase 1
(SOD1) gene mutations as being responsible for some forms of fALS,5
many other genes linked to ALS have been identified.4 The most
frequent altered gene in both sALS and fALS is C9ORF72.6 Other rele-
vant genes are TAR DNA-binding protein (TARDBP), encoding for TDP‐43,
and fused in sarcoma (FUS), which encode for proteins implicated in the
regulation of RNA processing and expression.4 Intracellular inclusions of
TDP‐43 are the main pathological substrate of sporadic and familial
forms of ALS, except for those associated with SOD1mutations.7-9
Understanding the etiology of ALS and the factors that influence
its progression is crucial for the implementation of effective thera-
peutic strategies that are urgently needed. Although specific causes
leading to ALS are unknown, different cellular mechanisms were pro-
posed to mediate MN degeneration, such as glutamate excitotoxic-
ity, mitochondrial dysfunction, protein aggregation, proteasomal and
autophagic dysfunction, neuroinflammation, altered axonal transport,
and impaired RNA metabolism.1 In this context, the role of alter-
ations of RNA metabolism seems particularly central, especially con-
sidering that TDP43 and FUS are key components of coding and
noncoding RNA processing.
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MicroRNAs (miRNAs) are short noncoding RNAs that exert a piv-
otal role in the regulation of gene expression of many relevant phys-
iological processes and, also, in MNs.10,11 miRNAs bind to Argonaute
(AGO) proteins to form a ribonucleoprotein (RNP) complex and rec-
ognize complementary sequences of messenger RNA (mRNA) via
base‐pairing, inducing the down‐regulation of RNA targets.10,12 How-
ever, because physiological cellular processes need a complex regula-
tory mechanism, dysregulation of these molecular pathways, typically
occurring in chronic diseases, lead to a similarly complex dysregula-
tion of the miRNA expression profile. Indeed, the alterations of each
specific miRNA and, consequently, of pathways in which they are
involved are variable in different tissues and different disorders.
The finding that miRNAs are essential to MN physiology and sur-
vival, supported by the observation that transgenic mice that do not
process miRNAs and show hallmarks of MN degeneration,13
prompted the investigation of the role of miRNAs in MN diseases, in
particular ALS and type 1 spinal muscular atrophy (SMA) (reviewed
by us elsewhere).14,15 In both these conditions, the miRNA expres-
sion profile was shown to be deregulated both in the central ner-
vous system (CNS) and peripheral tissues, with ALS displaying a
more profound global dysregulation.14 Deregulation in the miRNA
expression pattern was reported in several tissues from ALS patients,
in particular in the spinal cord, brain, blood, and cerebrospinal fluid
(CSF), and it was also demonstrated in induced pluripotent stem cells
(iPSCs) generated from affected patients.14 The human spinal cord
miRNA expression profile showed a substantial global down‐regula-
tion in motor neuron disease,16 and this alteration was then demon-
strated to be particular to MNs.17 These findings have been related
to the inhibition of DICER, an endoribonuclease involved in the pro-
cessing of pre‐miRNA molecules.17 Remarkably, miRNA reduction
was found also in fibroblasts and was confirmed in serum, plasma,
CSF, and the motor cortex.18-22
The most constant finding in ALS mutant SOD1 rodents is an
increase in miR‐9 and miR‐206.23-26 In particular, the miR‐9 level is
increased in ALS rodent spinal cords,24,26 whereas the miR‐206 level
is increased in skeletal muscles in both SOD1 and SMA murine mod-
els.27 Remarkably, the reduction in miR‐206 has a negative effect on
the ALS disease course in mice, suggesting that it could exert a pro-
tective role.23 Additionally, a constant increase in the miR‐206 level
in skeletal muscle28,29 and in serum has been described in ALS
patients.25,29 This finding may be associated with clinical progression,
suggesting that miR‐206 may represent a biomarker in motor neuron
disorders, particularly ALS.29
Furthermore, miRNAs are key elements in the regulation of cell
death, which is the crucial event in the pathophysiology of MN dis-
orders. Programmed cell death (PCD), which has been considered an
analogue to apoptosis until recently, was actually extended to
include other mechanisms of regulated necrosis (RN), specifically
necroptosis. Both apoptosis and necroptosis exert a significant role
in ALS MN death.30-32 In fact, although ALS can represent a rather
heterogeneous group of diseases, one of the final common patho-
genic elements is represented by MN death, which can serve also as
a common therapeutic target in addition to the etiology of ALS.
In this review, we present relevant information pertaining to the
miRNA role as modulators of apoptosis and RN pathways in ALS
(Figure 1, Table 1), considering both their possible pathogenic role
and their use as therapeutic targets.
2 | miRNAs AND INTRINSIC APOPTOSIS
Apoptosis is classically defined as PCD, or intracellular processes‐
mediated cell death.
The term ‘intrinsic apoptosis’ refers to mitochondrial‐related
apoptosis. It can be triggered by intracellular pathogenic injuries, such
as oxidative stress or DNA damage, and it is regulated by the BCL2
protein.32-34 Under normal conditions, the anti‐apoptotic protein
BCL2 inhibits apoptosis by blocking dimerization of the pro‐apoptotic
molecules BAX and BAK.33,34 In the presence of pathological stimuli,
the BCL2 protein is hindered by the pro‐apoptotic BH3‐only proteins,
favouring BAX and BAK dimerization on the outer mitochondrial
membrane. BAX and BAK binding promotes permeabilization of the
mitochondrial outer membrane and cytochrome c (cyt c) release into
the cytoplasm. Cytosolic cyt c binds apoptotic protease activating
factor‐1 (Apaf‐1) to facilitate formation of the multiprotein complex
the apoptosome, which stimulates caspase‐9. Caspase‐9 activation
further facilitates the caspase cascade, including caspase‐3, and the
completion of apoptosis.33,34
Intrinsic apoptosis can be controlled by several miRNAs, and a
group of miRNAs are also dysregulated in ALS. Among them, miR‐
125b and miR‐155 were found to display both pro‐apoptotic and
anti‐apoptotic properties. Specifically, they participate in BCL2 inhi-
bition in response to CD154 (CD40 ligand) in human leukemic
B‐cells,35 thus activating the apoptotic process.
Nevertheless, miR‐125b is known as a negative regulator of
p53,36 which in turn is a mediator of apoptotic pathways during cell
stress. Finally, miR‐125b was reported to target the 7sl long noncod-
ing RNA (lncRNA) as well,37 and because lncRNA is a p53 repressor,
this may also contribute to its pro‐apoptotic properties.
miR‐125b was demonstrated to be up‐regulated in the CNS of
SOD1‐G93A mice, correlating with neurodegeneration and astrocy-
tosis.38 miR‐125b and miR‐155 levels were also augmented in the
microglia of SOD1G93A mice, where they promote neuroinflamma-
tion.39 Increased miR‐155 expression was demonstrated in the ALS
spinal cord, with a fivefold increase in rodent and twofold increase
in patients samples.40 Anti‐miR‐155 prompted generalized de‐repres-
sion of mRNA targets in peritoneal macrophages and was found to
disseminate in the mouse brain and spinal cord after intraventricular
delivery. Treatment of SOD1‐G93A mice with anti‐miR‐155 signifi-
cantly increased disease duration by 15 days and life length by
10 days.40 These data were confirmed by another set of experiments
demonstrating that intraventricular delivery of anti‐miR‐155 reversed
the expression of microglial miR‐155 targeted genes and that periph-
eral anti‐miR‐155 administration extended the lifespan.41 Moreover,
abnormal microglia and monocyte signatures were recovered after
genetic deletion of microglial miR‐155, and the lifespan of SOD1
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mice increased by 51 days in females and 27 days in male animals.41
miR‐155 appears to be consistently over‐expressed in ALS in differ-
ent studies and may be a biomarker for early disease identification.42
Several other miRNAs, including miR‐195, miR‐24, and miR‐
365‐2, regulate the anti‐apoptotic protein BCL2 by targeting the
3′‐UTR.43 Up‐regulation of these molecules promotes PCD in breast
cancer cells otherwise resistant to apoptosis. Additionally, miR‐365
and miR‐24 are dysregulated in microglia ALS.39
Apaf‐1, a key element of the apoptosome, is regulated by four
RNA molecules (miR‐23a/b and miR‐27a/b), which assemble,
forming two miRNA clusters, miR‐23a‐27a‐24 and miR‐23b‐27b‐
24.44 MiR‐23a/b and miR‐27a/b inhibited Apaf‐1 expression
in vitro, and their levels were inversely correlated with Apaf‐1
levels in the mouse cortex. Indeed, whereas hypoxic injuries
induce the down‐regulation of miR‐23b and miR‐27b and increase
Apaf‐1 expression in mouse neurons, overexpression of the two
miRNAs in transgenic mice suppressed the apoptosis of neural
cells induced by hypoxia.44 These findings indicate that these miR-
NAs may represent potential therapeutic strategies in neuronal
apoptosis‐related diseases.
F IGURE 1 Cell death pathways currently implicated in motor neuron cell death in ALS and related miRNAs. (A) Extrinsic apoptosis. Fas
ligand (FASL) activation of the cognate FAS death receptor induces intracellular formation of the death‐inducing signalling complex (DISC),
which in turn interacts with Fas‐associated protein with death domain (FADD) through their death effector domains, inducing the recruitment
and dissociation of pro‐caspase‐8 from the DISC. Activated caspase‐8 initiates the caspase cascade and leads to apoptosis through caspase‐3
activation. miR‐375 can promote the extrinsic pathway by various mechanisms. miR‐375, miR‐125b, and miR‐27a/b can inhibit the extrinsic
pathway by silencing p53. miR‐21 can inhibit the extrinsic pathway by targeting FasL. (B) Intrinsic apoptosis. Following cytotoxic stimuli, pro‐
apoptotic BH3‐only proteins silence the anti‐apoptotic protein BCL2, effectively allowing BAX and BAK to dimerize. This dimerization makes
the outer mitochondrial membrane permeable and allows cytochrome_c (cyt_c) release into the cytoplasm. The cyt_c binding to apoptotic
protease activating factor‐1 (Apaf‐1) prompts formation of the apoptosome, which activates caspase‐9 and the caspase cascade, in which
apoptosis is ultimately driven by caspase‐3 activation. MiR‐125b, miR‐155, miR‐365, miR‐24, miR‐1, and miR‐21 promote apoptosis by
silencing BCL2. MiR‐133a inhibits apoptosis by silencing caspase‐9. MiR‐23, miR‐27, miR‐1, miR‐21, and miR‐26 inhibit intrinsic apoptosis, and
miR‐23 has also pro‐apoptotic properties. (C) Necroptosis. Necroptosis is favoured by low levels of caspase‐8, combined with sufficient
concentrations of receptor‐interacting protein 3 (RIP3) and mixed lineage kinase domain like pseudokinase (MLKL). Following tumour necrosis
factor receptor 1 (TNFR1) stimulation by tumour necrosis factor (TNF), RIP1 interacts with RIP3, and its phosphorylation is activated MLKL.
They form a complex called the necrosome, which causes cell membrane rupture. miR‐155 inhibits necroptosis by silencing RIP1
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By contrast, it was shown that miR‐23a can exert a pro‐apoptotic
role by inhibiting X‐linked inhibitor of apoptosis protein (XIAP),
which binds and inhibits caspase 3, 7, and 9. Specifically, various
miRNAs, such as miR‐23a, miR‐24, and the miR‐130 cluster, bind to
the XIAP 3′‐UTR, inducing apoptosis.45
Compared to healthy controls, miR‐23a, along with miR‐29b,
miR‐206, and miR‐455, was up‐regulated in the skeletal muscle of
ALS subjects.28 In this context, miR‐23a caused a decrease in
peroxisome proliferator‐activated receptor γ coactivator‐1α (PGC‐1α)
protein expression in ALS tissue. This potentially has a negative
effect on skeletal muscle mitochondrial function.28 miR‐27a was
found diminished in the serum of ALS patients compared to healthy
individuals.46
miR‐133 and miR‐1 are normally present in adult skeletal muscle
and cardiomyocytes. miR‐133 binds caspase‐9 at its 3′‐UTR binding
site, and it's up‐regulation by ischaemic postconditioning or through
TABLE 1 miRNAs modulating apoptosis and necroptosis pathways in ALS
miRNA Target molecule Regulatory effect
Apoptosis/Necroptosis
pathways Data in ALS
miR‐125b BCL2 Pro‐apoptotic35 Intrinsic apoptosis Up‐regulated in the CNS of SOD1G93A mice38,39
7sl lncRNA Pro‐apoptotic37
Anti‐apoptotic36
p53 Extrinsic apoptosis
miR‐155 BCL2 Pro‐apoptotic35 Intrinsic apoptosis Up‐regulated in microglia of SOD1G93A mice39
Increased in the ALS spinal cord: fivefold in mice and
twofold in humans40
Anti‐miR‐155 prolonged survival in SOD1 mice40,41
Anti‐necroptotic77
RIP1 Necroptosis
miR‐365 and
miR‐24
BCL2 Pro‐apoptotic43 Intrinsic aptoptosis Dysregulated in microglia ALS mice39
miR‐23a/b Apaf‐1 Anti‐apoptotic44 Intrinsic aptoptosis Increased in skeletal muscle of ALS patients; influence on
mitochondrial function28Pro‐apoptotic45
XIAP Intrinsic aptoptosis
miR‐27a/b Apaf‐1 Anti‐apoptotic44 Intrinsic apoptosis Reduced in serum of ALS patients46
Pro‐apoptotic68
FADD Extrinsic apoptosis
miR‐133a Caspase‐9 Anti‐apoptotic47 Intrinsic aptoptosis Reduced in in SOD1G93A mice muscle26
miR‐1 Unknown Anti‐apoptotic47 Intrinsic aptoptosis Reduced in in SOD1G93A mice muscle26
BCL2, HSP60,
HSP70
Pro‐apoptotic48 Intrinsic aptoptosis
miR‐29a MCL‐1, P85a,
CDC42
Pro‐apoptotic48,50 Intrinsic aptoptosis Reduced in SOD1G93A mice muscle26
Increased in the lumbar spinal cord of ALS SOD1G3A mice49
miR‐375 cIAP?
cFLIP‐L?
p53, ELAVL4
Pro‐apoptotic69 Extrinsic apoptosis Reduced in ALS iPSCs‐derived MNs carrying FUS mutations71
Anti‐apoptotic70
miR‐34a BCL2 Pro‐apoptotic56,57 Intrinsic apoptosis Decreased in SOD1G93A mice brainstem and spinal cord62
SIRT1
miR‐26 MTDH EZH2 Pro‐apoptotic59 Intrinsic and extrinsic
apoptosis
Decreased in SOD1G93A mice brainstem and spinal cord62
miR‐21 BCL2, TGFBR2,
Pdcd4
Anti‐apoptotic65 Intrinsic apoptosis Increased in spinal cord and decreased in brainstem
of SOD1G93A mice62
PPARα, FASL Extrinsic apoptosis
PTEN Intrinisc and extrinsic
apoptosis
ALS: Amyotrophic lateral sclerosis; Apaf‐1: apoptotic protease activating factor‐1; CDC42: cell division control protein 42 homolog; cFLIP‐L: cellular
FLICE (FADD‐like IL‐1β‐converting enzyme)‐inhibitory protein; cIAP: Cellular inhibitor of apoptosis 1; CNS: central nervous system; FADD: Fas‐asso-
ciated protein with death domain; FASL: Fas Ligand; ELAVL4: ELAV‐like protein 4; EZH2: enhancer of zeste homolog 2; iPSCs: induced pluripotent stem
cells; lncRNA: long noncoding RNA; miRNA: micro‐RNA; MCL‐1: induced myeloid leukaemia cell differentiation; MNs: motor neurons; MTDH: Metad-
herin; Pdcd4: programmed cell death 4; PPARα: peroxisome proliferator activated receptor alpha; PTEN: phosphatase and tensin homolog; RIP1: recep-
tor‐interacting protein 1; SIRT1: silent information regulator 1; TGFBR2: transforming growth factor beta receptor II; XIAP: X‐linked inhibitor of
apoptosis protein.
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miRNA mimics prevents apoptosis induced by ischaemia‐reperfusion
in rat hearts.47 miR‐1 is proposed to promote intrinsic apoptosis by
regulating BCL2, HSP60 and HSP7048; however, it is reported that
along with miR‐133a, it plays a key role in protecting myocardial
cells in case of damage, suppressing apoptosis‐associated genes.47
Several physiological or pathological events impact miRNA
expression, in turn activating or inhibiting the intrinsic apoptotic
pathway. For example, in ischaemia‐reperfusion heart damage,
altered levels of several miRNAs, such as miR‐1, miR‐21, miR‐29, and
miR‐133, modify the expression of several miRNA‐targeted genes,
including Bcl-2, PTEN, Mcl-1, HSP20, HSP60, HSP70, LRRFIP1, Pdcd4,
and Sirt-1, which can independently or jointly prompt intrinsic apop-
tosis and influence tissue damage.48
Several of the above cited miRNAs were found altered in
SOD1G93A rodent muscle tissue; in particular, miR‐1, miR‐29, and
miR‐133 were reduced compared to wild‐type. This local expression
can influence the CNS mRNA patterns, particularly those linked with
the myelination events in the spinal cord.26 Otherwise, higher
expression of miR‐29a, which is specific for the CNS, has been
observed from postnatal day 70 in the lumbar tract of the SOD1G3A
mouse spinal cord compared to controls.49 After miR‐29a knock-
down obtained by a one‐time intraventricular administration of a
miR‐29a‐specific antagomir in the CNS, miR‐29 down‐regulation did
not show amelioration in terms of disease progression and motor
performance, despite a slight increase in lifespan in male mice.49
Indeed, up‐regulation of miR‐29 caused a reduction in the induced
myeloid leukaemia cell differentiation (MCL‐1) protein, which, when
expressed, has an anti‐apoptotic role similar to BCL2.50
The miR‐34 family comprises three miRNAs encoded by two dif-
ferent loci: the miR‐34a locus is located on chromosome 1, whereas
the miR‐34b/34c cluster is located on chromosome 11. Although the
latter is expressed in lungs, miR‐34 is ubiquitous, with the greatest
level in the brain.51 mir‐34a has a role in cell death, particularly in
caspase‐dependent apoptosis, which has been extensively recog-
nized.52 At first, ectopic expression of miR‐34a in neuroblastoma cell
lines (in which its levels are normally decreased) was found to induce
apoptosis.53 Then, Chang and colleagues reported that p53 induced
the up‐regulation of miR‐34a, which in turn regulates genes related
to cell proliferation, DNA repair and apoptosis, thus playing a crucial
role in p53‐dependent and independent apoptosis.54 These data
were confirmed by Bommer et al55, who demonstrated that miR‐34a
is one of the effectors of the p53 tumour suppressor function and
that BCL2 is one of its target genes. Moreover, BCL2 was found to
be down‐regulated by miR‐34a in a mouse model of Alzheimer's dis-
ease, and miR‐34a repression in cell lines resulted in up‐regulation of
the BCL2 protein and a decrease in caspase 3 levels.56 Silent infor-
mation regulator 1 (SIRT1) is a deacetylase that regulates apoptosis
induced by oxidative stress and DNA damage by inactivating several
molecular targets, including p53. miR‐34a was shown to inhibit
SIRT1, thus promoting activation of acetylated p53 and leading to
increased expression of its transcriptional target p21 and PUMA.57
Therefore, miR‐34a and p53 may promote apoptosis by regulating
each other through a positive feedback loop.
Similar to miR‐34, miR‐26 is an apoptosis‐involved miRNA that
exhibits different expression profiles in different biological and
pathologic processes, such as growth, development, and tumourigen-
esis.58 It was found down‐regulated in several types of tumours,
where it likely exerts a tumour‐suppressor function, and it is over‐
expressed in gliomas, where it promotes cell growth and proliferation
by regulating one of its target, PTEN. In particular, miR‐26 prompted
activation of caspase‐9 and caspase‐8, inducing both intrinsic and
extrinsic apoptosis, respectively, in human breast cancer cells by tar-
geting EZH2 and MTDH.59 The latter gene, which encodes for a his-
tone‐methyltransferase enzyme involved in transcriptional
repression, is also silenced during myogenesis, suggesting a role for
miR‐26 in the regulation of proliferation and differentiation.60 Finally,
through autophagy inhibition, miR‐26 increased apoptosis in hepato-
cellular carcinoma cells.61
A decrease in miR‐34a and miR‐26b levels was found in the
spinal cord and brainstem nuclei of SOD1‐G93A rodent models.62
Finally, given its constant over‐expression in numerous cancers,
miR‐21 has been widely studied in oncology for its anti‐apoptotic
properties. At first, miR‐21 knockdown was shown to increase
apoptotic cell death in murine models and in human glioblastoma
cells.63,64 Then, a number of tumour‐suppressor genes implicated in
apoptosis were identified as targets of miR‐21 regulation. Among
them are molecules involved in intrinsic apoptosis, such as the
anti‐apoptotic protein BCL2, transforming growth factor beta
receptor II (TGFBR2), which participates in the pro‐apoptotic sig-
nalling of TGF‐beta, programmed cell death 4 (Pdcd4), a pro‐apop-
totic gene found up‐regulated in hepatocellular cancer, and other
proteins participating in the extrinsic pathway, such Fas‐ligand
(FASL) and peroxisome proliferator activated receptor alpha
(PPARα).65 Phosphatase and tensin homolog (PTEN), one of the
most important miR‐21 targets, is a mediator of both intrinsic and
extrinsic apoptosis because it has a role in both mitochondrial and
tumour necrosis factor (TNF) signalling.
Although its role in ALS has not been completely recognized,
over‐expression in the spinal cord and down‐regulation in the brain-
stem were described in mouse models.62 Indeed, it may play a func-
tion in glial interplay and the inflammatory response because it
regulates astrocyte hypertrophy and scar formation after a spinal
cord injury.66
3 | miRNA AND EXTRINSIC APOPTOSIS
Extrinsic apoptosis is triggered by the binding of extracellular ligands
to specific surface receptors, called death receptors (DRs). The most
well‐characterized DRs belong to the TNF family, such as TNF
receptor 1 (TNFR1) and Fas. Ligand binding and activation cause the
assembly of the death‐inducing signalling complex (DISC), which in
turn cooperates with the adaptor protein Fas‐associated protein with
death domain (FADD), mediated by their death effector domains
(DEDs). This interplay leads to the release and cleavage of pro‐
caspase‐8 that once activated, prompts a caspase signalling cascade
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that ultimately elicits apoptosis. Several miRNAs can selectively rec-
ognize and inhibit death ligands and receptors.
As previously noted, miR‐125b targets p53, preventing cellular
death, likely through a nonintrinsic‐cell mechanism.67
In human embryonic kidney cells, the miRNA cluster miR‐23a‐
27a‐24 may separately promote either caspase‐dependent or inde-
pendent apoptosis by silencing FADD expression.68 In particular,
FADD is expected to be the target of miR‐27a based on a bioinfor-
matics target prediction algorithm; its levels are increased propor-
tionally to a low level of miR‐27a, and its expression was found to
be directly inhibited by miR‐27a binding to its target sequence.68
Moreover, the miR‐23a‐27a‐24 cluster enhances TNFα cytotoxicity
by increasing the expression of TNF receptor associated factor 2
(TRAF‐2) protein, which is an effector of TNFR1 signalling. As dis-
cussed above, serum miR‐27a was reduced in ALS patients.46
miR‐375 also increases TNFα‐induced apoptosis, although the
mechanisms are unclear, although reductions in both cellular
inhibitor of apoptosis 1 (cIAP) and cellular FLICE (FADD‐like IL‐1β‐
converting enzyme)‐inhibitory protein (cFLIP‐L) by miR‐375 have
been described.69
miR‐375 is implicated in the motor neuron disease phenotype,
likely playing a protective role.70 miR‐375 is implicated in neurogen-
esis, inducing cell proliferation and protecting MNs from DNA dam-
age‐induced apoptosis.70 Moreover, MNs derived from an SMA
patient presented low levels of miR‐375, increased expression of
p53 protein, and increased susceptibility to apoptosis in response to
DNA damage.70 Remarkably, it was recently shown that miR‐375
levels were also diminished in ALS induced pluripotent stem cells
(iPSCs)‐derived MNs harbouring FUS pathogenic mutations.71
Accordingly, FUS mutant MNs displayed an over‐expression of p53
and other pro‐apoptotic miR‐375 predicted targets, such as ELAV‐
like protein 4 (ELAVL4). Indeed, ALS spinal MNs present increased
levels of p53 protein, which may be the main driver of neuronal
death mediated by apoptotic mechanisms.72
Thus, miR‐375 dysregulation is a condition shared by two differ-
ent motor neuron disorders, SMA70 and FUS‐ALS71 MNs, and miR‐
375 was reduced by 40% and 40%‐50%, respectively. The molecular
mechanisms of miR‐375 dysregulation in SMA are unknown at pre-
sent; however, it was hypothesized that FUS loss‐of‐function muta-
tions in ALS are responsible for FUS protein discharge from the
nucleus and interruption of miR‐375 synthesis.
Moreover, in addition to p53‐mediated apoptosis, miR‐375 reduc-
tion may have effects on other relevant pathways. It was associated
with an up‐regulation of its target ELAVL4, an RNA‐binding protein
implicated in CNS development, functioning, and plasticity.73 For this
reason, it was proposed that FUS/miR‐375/ELAVL4 signalling could be
a regulatory pathway involved in the RNA metabolism of MNs.71
4 | miRNA AND PROGRAMMED NECROSIS
Necrosis was traditionally considered an unprogrammed and prema-
ture cell death caused by damage from pathologic external stress,
resulting in cell disruption and outflow of cell content from the
nucleus and cytoplasm, which in turn can represent pro‐inflammatory
signals.32 Nevertheless, this hypothesis has been questioned by
recent evidence suggesting that necrosis can also be a regulated
process, sharing some features with apoptosis. One type of RN is
called necroptosis. Similar to apoptosis, necroptosis is a type of PCD
and involves DRs of the TNF family. By contrast, it is a caspase‐
independent mechanism, induces membrane disruption and the
release of cellular contents into the extracellular matrix, and
activates the immune response.32
This process can be triggered by ligation of TNF‐α to its receptor
TNFR1, and it is promoted when caspase‐8 is inhibited or
reduced.74,75 It is mediated by receptor‐interacting protein 1 (RIP1)
and RIP3, which, along with the mixed lineage kinase domain like
pseudokinase (MLKL), form a complex called the necrosome that
causes the formation of pores in the cell membrane and finally its
rupture.76
Re et al30 suggested that necroptosis participates in MN death in
sALS. They demonstrated that in a coculture of MNs derived from
human embryonic stem cells with astrocytes obtained from post-
mortem sALS patient CNS, unlike controls, the sALS astrocytes
induced MN toxicity after 7 days. Treatment with a RIP1 antagonist,
necrostatin‐1, and Rip1 shRNA knockdown increased the number of
surviving MNs. Furthermore, treatment with necrosulfonamide, an
MLKL inhibitor, led to similar improvement. Thus, these results pro-
vided evidence that a caspase‐independent form of PCD, necropto-
sis, has a leading role in MN death in sALS, both in in vitro and
in vivo models.30 Additional findings in support of necroptosis in
motor neuron disorders came from Ito and colleagues, who
described the presence of this form of RN, both in cellular and ani-
mal models and in postmortem human samples, demonstrating the
presence of increased levels of RIP1, RIP3, and MLKL.31 miR‐155
recognizes RIP1 as a target and was demonstrated to be over‐
expressed after hydrogen‐peroxide administration in cardiomyocyte
progenitor cells. Thus, miR‐155 can inhibit necroptosis in a similar
manner as necrostatin.77 As mentioned above, increased miR‐155
levels were detected in the ALS CNS,40 with an unclear effect on
necroptosis.
5 | miR ‐9 AND ‐206 AND CELL DEATH
As noted above, the most constant finding in ALS rodent and human
tissues is the increase in miR‐9 in the CNS and miR‐206 in skeletal
muscle and serum.23-26
MiR‐9 is an miRNA highly expressed in the nervous system,
which regulates neurogenesis by inhibiting neural stem cell self‐
renewal and promoting neural differentiation and proliferation. As a
master regulator of neurogenesis, a potential role for miR‐9 in apop-
tosis was supported by the observation that miR‐9 down‐regulation
significantly increased cell death in the forebrain of Xenopus
embryos. By contrast, apoptosis did not occur in Xenopus embryo
hindbrains and in other model systems.78 In particular, it was
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described that an anti‐miR‐9 morpholino causes apoptosis in neural
progenitor cells (NPCs) only in the forebrain, with mechanisms that
involve the p53 pathway.79 Moreover, there is strong evidence for
the function of miR‐9 in neurodegeneration, and up‐regulation of
this miRNA was reported in postmortem brains of patients affected
by Alzheimer's disease and reduced levels in the precocious stages
of Huntington's disease. Finally, miR‐9 is down‐regulated in mouse
embryonic cell‐derived MNs carrying the SMN1 mutation and modify
the expression and dynamics of intermediate filaments.78 It is
unclear whether the specific effect of miR‐9 up‐regulation in the
CNS is positive or detrimental; however, it is uncontroversial that
miR‐9 down‐regulation in the spinal cord causes neurofilament dys-
regulation and MN degeneration.13 Additionally, miR‐9 is implicated
in cell proliferation and migration. As altered miR‐9 levels were
described in different types of cancer, miR‐9 is also likely implicated
in tumour formation and development. In consideration of the vari-
ety of its targets, miR‐9 may have different effects on several types
of cells and tissue, either inducing proliferation or cell death.78
Overall, these findings suggest that miR‐9 has different roles in
different contexts, and considering its dysregulation in MNs, proper
modulation with drugs or gene therapy could represent an interesting
challenge.
miR‐206 along with miR‐1 and miR‐133 are among the best
characterized human and mouse muscle‐specific miRNAs. They are
implicated in various steps of the muscle differentiation processes,
including alternative splicing, DNA synthesis, and cell apoptosis.80
During development, miR‐1 and miR‐206 inhibit target paired‐box
transcription factor 7 (Pax7) and its homolog Pax3, thus restricting
satellite cell proliferative potential and promoting their differentia-
tion in myogenic progenitor cells.81 Conversely, miR‐1 and miR‐206
down‐regulation provokes Pax7 and Pax3 overexpression and, sub-
sequently, inhibition of myoblast differentiation. In this context,
because Pax7 and Pax3 are pro‐survival factors, their down‐regula-
tion by miR‐206 can cause apoptosis. It is well‐known that ALS is
associated with higher expression of miR‐206 in muscle tissue,
where it plays a protective role, and is necessary for the regenera-
tion of neuromuscular junctions after acute nerve injury.23 ALS
mouse models knocked‐out for the miR‐206 gene display later and
incomplete muscle reinnervation compared to SOD1G93A mice
wild‐type for this miRNA.82 It was recently reported that compared
to controls, ALS patients showed higher miR‐206 levels in plasma,
and interestingly, those values were correlated with muscle
strength measured by the Medical Research Council (MRC) scale
and were predictive of slower progression over 12 months.29 In
later disease stages, the miR‐206 concentration decreased in mus-
cle and serum, most likely reflecting a loss of muscle fibres. Con-
sidering this, miR‐206 could be a biomarker of lower MN
involvement and muscle damage in ALS29 and an interesting thera-
peutic target.
However, even if preliminary data in ALS rodents showed a
good therapeutic efficacy for its up‐regulation, a proper pharmaco-
logical/molecular modulation of miR‐206 may remain difficult in the
clinic.
6 | THERAPEUTIC PERSPECTIVES
In addition to providing interesting and reliable tools for understand-
ing the pathogenic mechanisms underlying ALS and other neurode-
generative disorders, miRNAs represent promising therapeutic
intervention strategies because the modulation of a single miRNA
molecule interferes with different target genes, thus modifying broad
cellular pathways and intervening at several levels in a complex dis-
ease such as ALS.
Approaches for miRNA modulation include (a) substitution of
down‐regulated miRNAs with synthetic miRNA mimics, which act at
the gene‐level inhibiting translation, (b) up‐regulated miRNA block-
ade and degradation through antisense oligonucleotides (anti‐miRs)
and antagomirs, (c) de‐repression of miRNA target genes through
miRNA masks, which bind to the 3′UTR of mRNA, hiding the miRNA
binding site, and (d) alteration of miRNA expression at the transcrip-
tion level using small drug inhibitors.83,84
Concerns limiting these procedures include the confined biodis-
tribution with systemic delivery and the capacity to pass the blood
brain barrier, which can be overcome using intrathecal infusion, and
the molecular stability over time. To improve miRNA cellular entry
and allow molecular stabilization against degradation, delivery vehi-
cles, such as liposomes, polymeric particles, and viral vectors, have
been developed. In this scenario, the adenovirus‐associated virus is
one of the most promising carriers.
Because in most cases miRNAs exert their function in multiple
pathways, the major issue of miRNA targeted therapy is the risk of
influencing the transcription of off‐target tissues, leading to the
occurrence of possible side effects.
Thus far, two miRNAs implicated in cell death were tested as
possible therapeutic targets in ALS: miR‐155 and miR‐29a. In both
cases, as described above, miRNA overexpression was inhibited with
an antagomir and a modest amelioration of the phenotype was
observed.40,49 No major side effects were recorded, although their
detection is limited by the reduced lifespan of SOD1G93A mice.
Considering that miR‐375 can preserve MNs from DNA damage‐
induced apoptosis via inhibition of p53 and given its down‐regulation
in ALS carrying the FUS mutation,71 miR‐375 can represent an inter-
esting therapeutic target. In this case, the up‐regulation of miR‐375
should be obtained.
Finally, because a global reduction in miRNA levels is a shared
molecular characteristic for different forms of motor neuron dis-
eases, strategies to generally up‐regulate their production, such as
enhancing DICER activity through small molecules, such as enoxacin,
can be explored.17
7 | CONCLUSION
Cell death, with various mechanisms spanning from apoptosis to
necroptosis, appears to be the final manner of MN loss in ALS. In
this context, it could represent a key aspect by which therapeutic
efforts can be rationally focused, in addition to a perfect knowledge
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of the primum movens of the disease. As important regulators of
cellular processes, including cell death, miRNAs can be potential tar-
gets for therapy development for motor neuron disorders. However,
because miRNAs can influence several targets within different
molecular pathways, their modification with pharmacological agents
or gene therapy strategies can be particularly complex. In this appar-
ently difficult scenario, several themes, such as the opportunity to
counteract the general depression of miRNAs in ALS or the specific
role of several miRNAs (ie, miR‐375, which can inhibit p53‐mediated
cell death) can emerge. These aspects, and hopefully new ones, war-
rant further investigation for the progress of therapeutic strategies
for ALS.
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